Article Figures & Data
Figures
- Figure 1.
Change in Mean HbA1c From Baseline at 104 Weeks
Reprinted from The Lancet Diabetes & Endocrinology, 2, Ridderstrale M et al, Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial, 691–700, Copyright 2014, with permission from Elsevier.
Tools
Empagliflozin Superior to Glimepiride as Second-line Treatment in T2DM
Permalink:
Table of contents
Cited By...
- No citing articles found.